Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis

Neuroscience

Volumn 191, Issue , 2011, Pages 6-21

  Luchetti, S ^a   Huitinga, I ^a   Swaab, D F ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

Alzheimer's disease; Brain; Human; Multiple sclerosis; Neurosteroids; Parkinson's disease

Indexed keywords

3ALPHA 5ALPHA TETRAHYDRODEOXYCORTICOSTERONE; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; ANDROGEN; ANDROSTENEDIONE; ESTROGEN; GANAXOLONE; GESTAGEN; GLUCOCORTICOID; MINERALOCORTICOID; NEUROSTEROID; PRASTERONE; PREGNANE DERIVATIVE; PREGNENOLONE; PROGESTERONE; TESTOSTERONE; TETRAHYDRODEOXYCORTICOSTERONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANDROGEN THERAPY; BASAL GANGLION; BRAIN LEVEL; CATAMENIAL EPILEPSY; COGNITION; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG MECHANISM; ESTROGEN THERAPY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEURAL STEM CELL; NEUROPROTECTION; NEUROTRANSMISSION; NIEMANN PICK DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEROIDOGENESIS;

ALZHEIMER DISEASE; ANIMALS; GENE EXPRESSION REGULATION; HUMANS; MULTIPLE SCLEROSIS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; RECEPTORS, GABA-A;

EID: 80052266362     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.04.010     Document Type: Review

References (201)

1. Aldred S., Mecocci P. Decreased dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) concentrations in plasma of Alzheimer's disease (AD) patients. Arch Gerontol Geriatr 2010, 51:e16-e18.
2. Andreen L., Nyberg S., Turkmen S., van Wingen G., Fernandez G., Backstrom T. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 2009, 34:1121-1132.
3. Azcoitia I., Sierra A., Veiga S., Garcia-Segura L.M. Aromatase expression by reactive astroglia is neuroprotective. Ann N Y Acad Sci 2003, 1007:298-305.
4. Barbaccia M.L., Costa E., Ferrero P., Guidotti A., Roy A., Sunderland T., Pickar D., Paul S.M., Goodwin F.K. Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease. Arch Gen Psychiatry 1986, 43:1143-1147.
5. Barbaccia M.L., Roscetti G., Trabucchi M., Purdy R.H., Mostallino M.C., Perra C., Concas A., Biggio G. Isoniazid-induced inhibition of GABAergic transmission enhances neurosteroid content in the rat brain. Neuropharmacology 1996, 35:1299-1305.
6. Barbaccia M.L., Serra M., Purdy R.H., Biggio G. Stress and neuroactive steroids. Int Rev Neurobiol 2001, 46:243-272.
7. Baulieu E.E., Robel P., Schumacher M. Neurosteroids: beginning of the story. Int Rev Neurobiol 2001, 46:1-32.
8. Bebo B.F., Fyfe-Johnson A., Adlard K., Beam A.G., Vandenbark A.A., Offner H. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol 2001, 166:2080-2089.
9. Behl C. Oestrogen as a neuroprotective hormone. Nat Rev Neurosci 2002, 3:433-442.
10. Belelli D., Casula A., Ling A., Lambert J.J. The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors. Neuropharmacology 2002, 43:651-661.
11. Belelli D., Lambert J.J. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 2005, 6:565-575.
12. Benavides J., Cornu P., Dennis T., Dubois A., Hauw J.J., MacKenzie E.T., Sazdovitch V., Scatton B. Imaging of human brain lesions with an omega 3 site radioligand. Ann Neurol 1988, 24:708-712.
13. Bernardi F., Pieri M., Stomati M., Luisi S., Palumbo M., Pluchino N., Ceccarelli C., Genazzani A.R. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women. Gynecol Endocrinol 2003, 17:65-77.
14. Beyenburg S., Watzka M., Clusmann H., Blumcke I., Bidlingmaier F., Elger C.E., Stoffel-Wagner B. Messenger RNA of steroid 21-hydroxylase (CYP21) is expressed in the human hippocampus. Neurosci Lett 2001, 308:111-114.
15. Bialek M., Zaremba P., Borowicz K.K., Czuczwar S.J. Neuroprotective role of testosterone in the nervous system. Pol J Pharmacol 2004, 56:509-518.
16. Biggio F., Gorini G., Caria S., Murru L., Mostallino M.C., Sanna E., Follesa P. Plastic neuronal changes in GABA(A) receptor gene expression induced by progesterone metabolites: in vitro molecular and functional studies. Pharmacol Biochem Behav 2006, 84:545-554.
17. Biggio G., Concas A., Follesa P., Sanna E., Serra M. Stress, ethanol, and neuroactive steroids. Pharmacol Ther 2007, 116:140-171.
18. Birzniece V., Backstrom T., Johansson I.M., Lindblad C., Lundgren P., Lofgren M., Olsson T., Ragagnin G., Taube M., Turkmen S., Wahlstrom G., Wang M.D., Wihlback A.C., Zhu D. Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems. Brain Res Rev 2006, 51:212-239.
19. Bixo M., Andersson A., Winblad B., Purdy R.H., Backstrom T. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 1997, 764:173-178.
20. Bixo M., Backstrom T., Winblad B., Andersson A. TEST and testosterone in specific regions of the human female brain in different endocrine states. J Steroid Biochem Mol Biol 1995, 55:297-303.
21. Bolam J.P., Smith Y. The GABA and substance P input to dopaminergic neurones in the substantia nigra of the rat. Brain Res 1990, 529:57-78.
22. Bossers K., Wirz K.T., Meerhoff G.F., Essing A.H., van Dongen J.W., Houba P., Kruse C.G., Verhaagen J., Swaab D.F. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain 2010, 133:3699-3723.
23. Bourque M., Dluzen D.E., Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 2009, 30:142-157.
24. Brinton R.D. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci 2008, 31:529-537.
25. Brinton R.D. Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends Pharmacol Sci 2009, 30:212-222.
26. Brinton R.D., Wang J.M. Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 2006, 3:11-17.
27. Brown R.C., Cascio C., Papadopoulos V. Pathways of neurosteroid biosynthesis in cell lines from human brain: regulation of dehydroepiandrosterone formation by oxidative stress and beta-amyloid peptide. J Neurochem 2000, 74:847-859.
28. Brown R.C., Han Z., Cascio C., Papadopoulos V. Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology. Neurobiol Aging 2003, 24:57-65.
29. Calabresi P., Centonze D., Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci 2000, 23:S57-S63.
30. Calon F., Morissette M., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 2003, 18:241-253.
31. Cardounel A., Regelson W., Kalimi M. Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc Soc Exp Biol Med 1999, 222:145-149.
32. Carroll B.J., Heath B., Jarrett D.B. Corticosteroids in brain tissue. Endocrinology 1975, 97:290-300.
33. Carroll J.C., Rosario E.R., Chang L., Stanczyk F.Z., Oddo S., LaFerla F.M., Pike C.J. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci 2007, 27:13357-13365.
34. Carter R.B., Wood P.L., Wieland S., Hawkinson J.E., Belelli D., Lambert J.J., White H.S., Wolf H.H., Mirsadeghi S., Tahir S.H., Bolger M.B., Lan N.C., Gee K.W. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther 1997, 280:1284-1295.
35. Cascio C., Prasad V.V., Lin Y.Y., Lieberman S., Papadopoulos V. Detection of P450c17-independent pathways for dehydroepiandrosterone (DHEA) biosynthesis in brain glial tumor cells. Proc Natl Acad Sci U S A 1998, 95:2862-2867.
36. Chen M.K., Baidoo K., Verina T., Guilarte T.R. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain 2004, 127:1379-1392.
37. Cherrier M.M., Matsumoto A.M., Amory J.K., Asthana S., Bremner W., Peskind E.R., Raskind M.A., Craft S. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 2005, 64:2063-2068.
38. Collinson N., Kuenzi F.M., Jarolimek W., Maubach K.A., Cothliff R., Sur C., Smith A., Otu F.M., Howell O., Atack J.R., McKernan R.M., Seabrook G.R., Dawson G.R., Whiting P.J., Rosahl T.W. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci 2002, 22:5572-5580.
39. Concas A., Follesa P., Barbaccia M.L., Purdy R.H., Biggio G. Physiological modulation of GABA(A) receptor plasticity by progesterone metabolites. Eur J Pharmacol 1999, 375:225-235.
40. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998, 339:285-291.
41. Corpechot C., Robel P., Axelson M., Sjovall J., Baulieu E.E. Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci U S A 1981, 78:4704-4707.
42. Correia S.C., Santos R.X., Cardoso S., Carvalho C., Santos M.S., Oliveira C.R., Moreira P.I. Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer's disease?. Curr Aging Sci 2010, 3:113-126.
43. Cosenza-Nashat M., Zhao M.L., Suh H.S., Morgan J., Natividad R., Morgello S., Lee S.C. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 2009, 35:306-328.
44. Costa E., Cheney D.L., Grayson D.R., Korneyev A., Longone P., Pani L., Romeo E., Zivkovich E., Guidotti A. Pharmacology of neurosteroid biosynthesis. Role of the mitochondrial DBI receptor (MDR) complex. Ann N Y Acad Sci 1994, 746:223-242.
45. Craig M.C., Murphy D.G. Estrogen therapy and Alzheimer's dementia. Ann N Y Acad Sci 2010, 1205:245-253.
46. De Nicola A.F., Labombarda F., Deniselle M.C., Gonzalez S.L., Garay L., Meyer M., Gargiulo G., Guennoun R., Schumacher M. Progesterone neuroprotection in traumatic CNS injury and motoneuron degeneration. Front Neuroendocrinol 2009, 30:173-187.
47. di Michele F., Longone P., Romeo E., Lucchetti S., Brusa L., Pierantozzi M., Bassi A., Bernardi G., Stanzione P. Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. Neurol Sci 2003, 24:172-173.
48. Djebaili M., Guo Q., Pettus E.H., Hoffman S.W., Stein D.G. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 2005, 22:106-118.
49. Doorduin J., de Vries E.F., Dierckx R.A., Klein H.C. PET imaging of the peripheral benzodiazepine receptor: monitoring disease progression and therapy response in neurodegenerative disorders. Curr Pharm Des 2008, 14:3297-3315.
50. Do Rego J.L., Seong J.Y., Burel D., Leprince J., Luu-The V., Tsutsui K., Tonon M.C., Pelletier G., Vaudry H. Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front Neuroendocrinol 2009, 30:259-301.
51. Do-Rego J.L., Mensah-Nyagan G.A., Beaujean D., Vaudry D., Sieghart W., Luu-The V., Pelletier G., Vaudry H. Gamma-aminobutyric acid, acting through gamma -aminobutyric acid type A receptors, inhibits the biosynthesis of neurosteroids in the frog hypothalamus. Proc Natl Acad Sci U S A 2000, 97:13925-13930.
52. Drummond E.S., Harvey A.R., Martins R.N. Androgens and Alzheimer's disease. Curr Opin Endocrinol Diabetes Obes 2009, 16:254-259.
53. El-Etr M., Ghoumari A., Sitruk-Ware R., Schumacher M. Hormonal influences in multiple sclerosis: new therapeutic benefits for steroids. Maturitas 2011, 68:47-51.
54. Engel S.R., Grant K.A. Neurosteroids and behavior. Int Rev Neurobiol 2001, 46:321-348.
55. Erkut Z.A., Endert E., Huitinga I., Swaab D.F. Cortisol is increased in postmortem cerebrospinal fluid of multiple sclerosis patients: relationship with cytokines and sepsis. Mult Scler 2002, 8:229-236.
56. Eser D., Baghai T.C., Schule C., Nothdurfter C., Rupprecht R. Neuroactive steroids as endogenous modulators of anxiety. Curr Pharm Des 2008, 14:3525-3533.
57. Farrant M., Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 2005, 6:215-229.
58. Ferrarese C., Appollonio I., Frigo M., Meregalli S., Piolti R., Tamma F., Frattola L. Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementia. Neurology 1990, 40:632-635.
59. Ferrero P., Benna P., Costa P., Tarenzi L., Baggio G., Bergamasco B., Bergamini L. Diazepam binding inhibitor-like immunoreactivity (DBI-LI) in human CSF. Correlations with neurological disorders. J Neurol Sci 1988, 87:327-349.
60. Follesa P., Mostallino M.C., Biggio F., Gorini G., Caria S., Busonero F., Murru L., Mura M.L., Sanna E., Biggio G. Distinct patterns of expression and regulation of GABA receptors containing the delta subunit in cerebellar granule and hippocampal neurons. J Neurochem 2005, 94:659-671.
61. Frye C.A. The role of neurosteroids and non-genomic effects of progestins and androgens in mediating sexual receptivity of rodents. Brain Res Brain Res Rev 2001, 37:201-222.
62. Garcia-Ovejero D., Azcoitia I., DonCarlos L.L., Melcangi R.C., Garcia-Segura L.M. Glia-neuron crosstalk in the neuroprotective mechanisms of sex steroid hormones. Brain Res Brain Res Rev 2005, 48:273-286.
63. Garcia-Segura L.M. Aromatase in the brain: not just for reproduction anymore. J Neuroendocrinol 2008, 20:705-712.
64. Garcia-Segura L.M., Sanz A., Mendez P. Cross-talk between IGF-I and estradiol in the brain: focus on neuroprotection. Neuroendocrinology 2006, 84:275-279.
65. Geese W.J., Raftogianis R.B. Biochemical characterization and tissue distribution of human SULT2B1. Biochem Biophys Res Commun 2001, 288:280-289.
66. Genazzani A.R., Pluchino N., Luisi S., Luisi M. Estrogen, cognition and female ageing. Hum Reprod Update 2007, 13:175-187.
67. George O., Vallee M., Le M.M., Mayo W. Neurosteroids and cholinergic systems: implications for sleep and cognitive processes and potential role of age-related changes. Psychopharmacology (Berl) 2006, 186:402-413.
68. Gerlach M., Gsell W., Kornhuber J., Jellinger K., Krieger V., Pantucek F., Vock R., Riederer P. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res 1996, 741:142-152.
69. Ghoumari A.M., Ibanez C., El-Etr M., Leclerc P., Eychenne B., O'Malley B.W., Baulieu E.E., Schumacher M. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J Neurochem 2003, 86:848-859.
70. Gillies G.E., McArthur S. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: a contribution to sex-specific neuroprotection by estrogens. Horm Behav 2010, 57:23-34.
71. Gold S.M., Mohr D.C., Huitinga I., Flachenecker P., Sternberg E.M., Heesen C. The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol 2005, 26:644-652.
72. Gold S.M., Voskuhl R.R. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res 2009, 175:239-251.
73. Gold S.M., Voskuhl R.R. Estrogen treatment in multiple sclerosis. J Neurol Sci 2009, 286:99-103.
74. Grasser A., Moller A., Backmund H., Yassouridis A., Holsboer F. Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis. Exp Clin Endocrinol Diabetes 1996, 104:31-37.
75. Griffin L.D., Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 1999, 96:13512-13517.
76. Gulyas B., Makkai B., Kasa P., Gulya K., Bakota L., Varszegi S., Beliczai Z., Andersson J., Csiba L., Thiele A., Dyrks T., Suhara T., Suzuki K., Higuchi M., Halldin C. A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochem Int 2009, 54:28-36.
77. Gursoy E., Cardounel A., Kalimi M. Pregnenolone protects mouse hippocampal (HT-22) cells against glutamate and amyloid beta protein toxicity. Neurochem Res 2001, 26:15-21.
78. Hammond G.L., Hirvonen J., Vihko R. Progesterone, androstenedione, testosterone, 5 alpha-dihydrotestosterone and androsterone concentrations in specific regions of the human brain. J Steroid Biochem 1983, 18:185-189.
79. He J., Evans C.O., Hoffman S.W., Oyesiku N.M., Stein D.G. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol 2004, 189:404-412.
80. Heesen C., Gold S.M., Raji A., Wiedemann K., Schulz K.H. Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis. Psychoneuroendocrinology 2002, 27:505-517.
81. Heidbrink C., Hausler S.F., Buttmann M., Ossadnik M., Strik H.M., Keller A., Buck D., Verbraak E., van Meurs M., Krockenberger M., Mehling M., Mittelbronn M., Laman J.D., Wiendl H., Wischhusen J. Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis. Brain Behav Immun 2010, 24:975-984.
82. Her C., Wood T.C., Eichler E.E., Mohrenweiser H.W., Ramagli L.S., Siciliano M.J., Weinshilboum R.M. Human hydroxysteroid sulfotransferase SULT2B1: two enzymes encoded by a single chromosome 19 gene. Genomics 1998, 53:284-295.
83. Herbert J., Goodyer I.M., Grossman A.B., Hastings M.H., de Kloet E.R., Lightman S.L., Lupien S.J., Roozendaal B., Seckl J.R. Do corticosteroids damage the brain?. J Neuroendocrinol 2006, 18:393-411.
84. Herd M.B., Belelli D., Lambert J.J. Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol Ther 2007, 116:20-34.
85. Hogervorst E. Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men. Evid Based Med 2008, 13:71.
86. Horak M., Vlcek K., Petrovic M., Chodounska H., Vyklicky L. Molecular mechanism of pregnenolone sulfate action at NR1/NR2B receptors. J Neurosci 2004, 24:10318-10325.
87. Howells D.W., Porritt M.J., Wong J.Y., Batchelor P.E., Kalnins R., Hughes A.J., Donnan G.A. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 2000, 166:127-135.
88. Inoue T., Akahira J., Suzuki T., Darnel A.D., Kaneko C., Takahashi K., Hatori M., Shirane R., Kumabe T., Kurokawa Y., Satomi S., Sasano H. Progesterone production and actions in the human central nervous system and neurogenic tumors. J Clin Endocrinol Metab 2002, 87:5325-5331.
89. Ishunina T.A., van B.D., van der Meulen G., Unmehopa U.A., Hol E.M., Huitinga I., Swaab D.F. Diminished aromatase immunoreactivity in the hypothalamus, but not in the basal forebrain nuclei in Alzheimer's disease. Neurobiol Aging 2005, 26:173-194.
90. Javitt N.B., Lee Y.C., Shimizu C., Fuda H., Strott C.A. Cholesterol and hydroxycholesterol sulfotransferases: identification, distinction from dehydroepiandrosterone sulfotransferase, and differential tissue expression. Endocrinology 2001, 142:2978-2984.
91. Karishma K.K., Herbert J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci 2002, 16:445-453.
92. Kask K., Backstrom T., Lundgren P., Sundstrom P.I. Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls. Pharmacol Biochem Behav 2009, 92:608-613.
93. Kim H.J., Kim J.E., Ha M., Kang S.S., Kim J.T., Park I.S., Paek S.H., Jung H.W., Kim D.G., Cho G.J., Choi W.S. Steroidogenic acute regulatory protein expression in the normal human brain and intracranial tumors. Brain Res 2003, 978:245-249.
94. Kim S., Liva S.M., Dalal M.A., Verity M.A., Voskuhl R.R. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology 1999, 52:1230-1238.
95. Kim S.B., Hill M., Kwak Y.T., Hampl R., Jo D.H., Morfin R. Neurosteroids: cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics. J Clin Endocrinol Metab 2003, 88:5199-5206.
96. Kimonides V.G., Khatibi N.H., Svendsen C.N., Sofroniew M.V., Herbert J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci U S A 1998, 95:1852-1857.
97. Kipp M., Beyer C. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front Neuroendocrinol 2009, 30:188-200.
98. Kish S.J., Rajput A., Gilbert J., Rozdilsky B., Chang L.J., Shannak K., Hornykiewicz O. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann Neurol 1986, 20:26-31.
99. Koenig H.L., Schumacher M., Ferzaz B., Thi A.N., Ressouches A., Guennoun R., Jung-Testas I., Robel P., Akwa Y., Baulieu E.E. Progesterone synthesis and myelin formation by Schwann cells. Science 1995, 268:1500-1503.
100. Koning N., Bo L., Hoek R.M., Huitinga I. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol 2007, 62:504-514.
101. Koning N., Swaab D.F., Hoek R.M., Huitinga I. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol 2009, 68:159-167.
102. Kreisl W.C., Fujita M., Fujimura Y., Kimura N., Jenko K.J., Kannan P., Hong J., Morse C.L., Zoghbi S.S., Gladding R.L., Jacobson S., Oh U., Pike V.W., Innis R.B. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 2010, 49:2924-2932.
103. Kumpfel T., Then B.F., Friess E., Uhr M., Yassouridis A., Trenkwalder C., Holsboer F. Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis. Neuroendocrinology 1999, 70:431-438.
104. Lacroix C., Fiet J., Benais J.P., Gueux B., Bonete R., Villette J.M., Gourmel B., Dreux C. Simultaneous radioimmunoassay of progesterone, androst-4-enedione, pregnenolone, dehydroepiandrosterone and 17-hydroxyprogesterone in specific regions of human brain. J Steroid Biochem 1987, 28:317-325.
105. Lanctot K.L., Herrmann N., Rothenburg L., Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer's disease. Int Psychogeriatr 2007, 19:151-158.
106. Lanthier A., Patwardhan V.V. Sex steroids and 5-en-3 beta-hydroxysteroids in specific regions of the human brain and cranial nerves. J Steroid Biochem 1986, 25:445-449.
107. Lavaque E., Sierra A., Azcoitia I., Garcia-Segura L.M. Steroidogenic acute regulatory protein in the brain. Neuroscience 2006, 138:741-747.
108. Leichtnam M.L., Rolland H., Wuthrich P., Guy R.H. Testosterone hormone replacement therapy: state-of-the-art and emerging technologies. Pharmacol Res 2006, 23:1117-1132.
109. Leitner H. Influence of neurosteroids on the pathogenesis of multiple sclerosis. Med Hypotheses 2010, 75:229-234.
110. Lethaby A., Hogervorst E., Richards M., Yesufu A., Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev 2008, CD003122.
111. Li R., Shen Y., Yang L.B., Lue L.F., Finch C., Rogers J. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. J Neurochem 2000, 75:1447-1454.
112. Longone P., Rupprecht R., Manieri G.A., Bernardi G., Romeo E., Pasini A. The complex roles of neurosteroids in depression and anxiety disorders. Neurochem Int 2008, 52:596-601.
113. Lowe S.L., Francis P.T., Procter A.W., Palmer A.M., Davison A.N., Bowen D.M. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain 1988, 111:785-799.
114. Lu P.H., Masterman D.A., Mulnard R., Cotman C., Miller B., Yaffe K., Reback E., Porter V., Swerdloff R., Cummings J.L. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 2006, 63:177-185.
115. Lucassen P.J., Muller M.B., Holsboer F., Bauer J., Holtrop A., Wouda J., Hoogendijk W.J., de Kloet E.R., Swaab D.F. Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol 2001, 158:453-468.
116. Luchetti S., Bossers K., Frajese G.V., Swaab D.F. Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease. Brain Pathol 2010, 20:945-951.
117. Luchetti S., Bossers K., Van de Bilt S., Agrapart V., Morales R.R., Frajese G.V., Swaab D.F. Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease. Neurobiol Aging 2009, 10.1016/j.neurobiolaging.2009.12.014.
118. Luchetti S., di M.F., Romeo E., Brusa L., Bernardi G., Cummings B.J., Longone P. Comparative non-radioactive RT-PCR assay: an approach to study the neurosteroids biosynthetic pathway in humans. J Neurosci Methods 2006, 153:290-298.
119. MacKenzie S.M., Dewar D., Stewart W., Fraser R., Connell J.M., Davies E. The transcription of steroidogenic genes in the human cerebellum and hippocampus: a comparative survey of normal and Alzheimer's tissue. J Endocrinol 2008, 196:123-130.
120. Majewska M.D., Schwartz R.D. Pregnenolone-sulfate: an endogenous antagonist of the gamma-aminobutyric acid receptor complex in brain?. Brain Res 1987, 404:355-360.
121. Mandrekar-Colucci S., Landreth G.E. Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets 2010, 9:156-167.
122. Marchetti B., Gallo F., Farinella Z., Tirolo C., Testa N., Caniglia S., Morale M.C. Gender, neuroendocrine-immune interactions and neuron-glial plasticity. Role of luteinizing hormone-releasing hormone (LHRH). Ann N Y Acad Sci 2000, 917:678-709.
123. Maric D., Liu Q.Y., Maric I., Chaudry S., Chang Y.H., Smith S.V., Sieghart W., Fritschy J.M., Barker J.L. GABA expression dominates neuronal lineage progression in the embryonic rat neocortex and facilitates neurite outgrowth via GABA(A) autoreceptor/Cl- channels. J Neurosci 2001, 21:2343-2360.
124. Marx C.E., Stevens R.D., Shampine L.J., Uzunova V., Trost W.T., Butterfield M.I., Massing M.W., Hamer R.M., Morrow A.L., Lieberman J.A. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology 2006, 31:1249-1263.
125. Marx C.E., Trost W.T., Shampine L.J., Stevens R.D., Hulette C.M., Steffens D.C., Ervin J.F., Butterfield M.I., Blazer D.G., Massing M.W., Lieberman J.A. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry 2006, 60:1287-1294.
126. Melcangi R.C., Cavarretta I., Magnaghi V., Ballabio M., Martini L., Motta M. Crosstalk between normal and tumoral brain cells. Effect on sex steroid metabolism. Endocrine 1998, 8:65-71.
127. Melcangi R.C., Garcia-Segura L.M., Mensah-Nyagan A.G. Neuroactive steroids: state of the art and new perspectives. Cell Mol Life Sci 2008, 65:777-797.
128. Melcangi R.C., Maggi R., Martini L. Testosterone and progesterone metabolism in the human neuroblastoma cell line SH-SY5Y. J Steroid Biochem Mol Biol 1993, 46:811-818.
129. Mellon S.H. Neurosteroid regulation of central nervous system development. Pharmacol Ther 2007, 116:107-124.
130. Mellon S.H., Gong W., Schonemann M.D. Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res Rev 2008, 57:410-420.
131. Mellon S.H., Miller W.L. Extraadrenal steroid 21-hydroxylation is not mediated by P450c21. J Clin Invest 1989, 84:1497-1502.
132. Migeon C.J., Keller A.R., Lawrence B., Shepard T.H. Dehydroepiandrosterone and androsterone levels in human plasma: effect of age and sex; day-to-day and diurnal variations. J Clin Endocrinol Metab 1957, 17:1051-1062.
133. Morita K., Her S. Progesterone pretreatment enhances serotonin-stimulated BDNF gene expression in rat c6 glioma cells through production of 5alpha-reduced neurosteroids. J Mol Neurosci 2008, 34:193-200.
134. Morley J.E., Kaiser F., Raum W.J., Perry H.M., Flood J.F., Jensen J., Silver A.J., Roberts E. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci U S A 1997, 94:7537-7542.
135. Mountjoy C.Q., Rossor M.N., Iversen L.L., Roth M. Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia. Brain 1984, 107:507-518.
136. Muller M.B., Lucassen P.J., Yassouridis A., Hoogendijk W.J., Holsboer F., Swaab D.F. Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci 2001, 14:1603-1612.
137. Naftolin F., Horvath T.L., Jakab R.L., Leranth C., Harada N., Balthazart J. Aromatase immunoreactivity in axon terminals of the vertebrate brain. An immunocytochemical study on quail, rat, monkey and human tissues. Neuroendocrinology 1996, 63:149-155.
138. Naylor J.C., Hulette C.M., Steffens D.C., Shampine L.J., Ervin J.F., Payne V.M., Massing M.W., Kilts J.D., Strauss J.L., Calhoun P.S., Calnaido R.P., Blazer D.G., Lieberman J.A., Madison R.D., Marx C.E. Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage. J Clin Endocrinol Metab 2008, 93:3173-3178.
139. Naylor J.C., Kilts J.D., Hulette C.M., Steffens D.C., Blazer D.G., Ervin J.F., Strauss J.L., Allen T.B., Massing M.W., Payne V.M., Youssef N.A., Shampine L.J., Marx C.E. Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects. Biochim Biophys Acta 2010, 1801:951-959.
140. Nohria V., Giller E. Ganaxolone. Neurotherapeutics 2007, 4:102-105.
141. Noorbakhsh F., Kristofor E., Ferdinand M., Baker G.B., Power C. Brain microRNAs targeting neurosteroidogenesis in multiple sclerosis mediate demyelination and neurodegeneration. 10th International Congress of Neuroimmunology. J Neuroimmunol 2010, 228:62.
142. Oh U., Fujita M., Ikonomidou V.N., Evangelou I.E., Matsuura E., Harberts E., Ohayon J., Pike V.W., Zhang Y., Zoghbi S.S., Innis R.B., Jacobson S. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol 2010, 10.1007/s11481-010-9243-6.
143. Orentreich N., Brind J.L., Vogelman J.H., Andres R., Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992, 75:1002-1004.
144. Otterness D.M., Weinshilboum R. Human dehydroepiandrosterone sulfotransferase: molecular cloning of cDNA and genomic DNA. Chem Biol Interact 1994, 92:145-159.
145. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapere J.J., Lindemann P., Norenberg M.D., Nutt D., Weizman A., Zhang M.R., Gavish M. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006, 27:402-409.
146. Pelletier G. Steroidogenic enzymes in the brain: morphological aspects. Prog Brain Res 2010, 181:193-207.
147. Perry T.L., Javoy-Agid F., Agid Y., Fibiger H.C. Striatal GABAergic neuronal activity is not reduced in Parkinson's disease. J Neurochem 1983, 40:1120-1123.
148. Pinna G., Agis-Balboa R.C., Pibiri F., Nelson M., Guidotti A., Costa E. Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice. Neurochem Res 2008, 33:1990-2007.
149. Platia M.P., Fencl M.D., Elkind-Hirsch K.E., Canick J.A., Tulchinsky D. Estrone sulfatase activity in the human brain and estrone sulfate levels in the normal menstrual cycle. J Steroid Biochem 1984, 21:237-241.
150. Reddy D.S. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions?. Trends Pharmacol Sci 2003, 24:103-106.
151. Reddy D.S. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res 2009, 85:1-30.
152. Reddy D.S., Rogawski M.A. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009, 6:392-401.
153. Reinikainen K.J., Paljarvi L., Huuskonen M., Soininen H., Laakso M., Riekkinen P.J. A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J Neurol Sci 1988, 84:101-116.
154. Rinne J.O., Halonen T., Riekkinen P.J., Rinne U.K. Free amino acids in the brain of patients with Parkinson's disease. Neurosci Lett 1988, 94:182-186.
155. Rissman R.A., De Blas A.L., Armstrong D.M. GABA(A) receptors in aging and Alzheimer's disease. J Neurochem 2007, 103:1285-1292.
156. Rosario E.R., Chang L., Head E.H., Stanczyk F.Z., Pike C.J. Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease. Neurobiol Aging 2011, 32:604-613.
157. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 2003, 28:139-168.
158. Ryan J., Scali J., Carriere I., Ritchie K., Ancelin M.L. Hormonal treatment, mild cognitive impairment and Alzheimer's disease. Int Psychogeriatr 2008, 20:47-56.
159. Sano M., Jacobs D., Andrews H., Bell K., Graff-Radford N., Lucas J., Rabins P., Bolla K., Tsai W.Y., Cross P., Andrews K., Costa R., Xiaodong L. A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics. Clin Trials 2008, 5:523-533.
160. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57:925-935.
161. Sasano H., Takashashi K., Satoh F., Nagura H., Harada N. Aromatase in the human central nervous system. Clin Endocrinol (Oxf) 1998, 48:325-329.
162. Schumacher M., Akwa Y., Guennoun R., Robert F., Labombarda F., Desarnaud F., Robel P., De Nicola A.F., Baulieu E.E. Steroid synthesis and metabolism in the nervous system: trophic and protective effects. J Neurocytol 2000, 29:307-326.
163. Schumacher M., Guennoun R., Stein D.G., De Nicola A.F. Progesterone: therapeutic opportunities for neuroprotection and myelin repair. Pharmacol Ther 2007, 116:77-106.
164. Schumacher M., Sitruk-Ware R., De Nicola A.F. Progesterone and progestins: neuroprotection and myelin repair. Curr Opin Pharmacol 2008, 8:740-746.
165. Schumacher M., Weill-Engerer S., Liere P., Robert F., Franklin R.J., Garcia-Segura L.M., Lambert J.J., Mayo W., Melcangi R.C., Parducz A., Suter U., Carelli C., Baulieu E.E., Akwa Y. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog Neurobiol 2003, 71:3-29.
166. Schwendimann R.N., Alekseeva N. Gender issues in multiple sclerosis. Int Rev Neurobiol 2007, 79:377-392.
167. Shirakawa H., Katsuki H., Kume T., Kaneko S., Akaike A. Pregnenolone sulphate attenuates AMPA cytotoxicity on rat cortical neurons. Eur J Neurosci 2005, 21:2329-2335.
168. Sicotte N.L., Liva S.M., Klutch R., Pfeiffer P., Bouvier S., Odesa S., Wu T.C., Voskuhl R.R. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002, 52:421-428.
169. Sierra A., Gottfried-Blackmore A., Milner T.A., McEwen B.S., Bulloch K. Steroid hormone receptor expression and function in microglia. Glia 2008, 56:659-674.
170. Smith C.D., Wekstein D.R., Markesbery W.R., Frye C.A. 3alpha,5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia. Psychopharmacology (Berl) 2006, 186:481-485.
171. Soldan S.S., Alvarez Retuerto A.I., Sicotte N.L., Voskuhl R.R. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 2003, 171:6267-6274.
172. Steckelbroeck S., Nassen A., Ugele B., Ludwig M., Watzka M., Reissinger A., Clusmann H., Lutjohann D., Siekmann L., Klingmuller D., Hans V.H. Steroid sulfatase (STS) expression in the human temporal lobe: enzyme activity, mRNA expression and immunohistochemistry study. J Neurochem 2004, 89:403-417.
173. Steckelbroeck S., Stoffel-Wagner B., Reichelt R., Schramm J., Bidlingmaier F., Siekmann L., Klingmuller D. Characterization of 17beta-hydroxysteroid dehydrogenase activity in brain tissue: testosterone formation in the human temporal lobe. J Neuroendocrinol 1999, 11:457-464.
174. Steckelbroeck S., Watzka M., Reichelt R., Hans V.H., Stoffel-Wagner B., Heidrich D.D., Schramm J., Bidlingmaier F., Klingmuller D. Characterization of the 5alpha-reductase-3alpha-hydroxysteroid dehydrogenase complex in the human brain. J Clin Endocrinol Metab 2001, 86:1324-1331.
175. Steckelbroeck S., Watzka M., Reissinger A., Wegener-Toper P., Bidlingmaier F., Bliesener N., Hans V.H., Clusmann H., Ludwig M., Siekmann L., Klingmuller D. Characterisation of estrogenic 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity in the human brain. J Steroid Biochem Mol Biol 2003, 86:79-92.
176. Steckelbroeck S., Watzka M., Stoffel-Wagner B., Hans V.H., Redel L., Clusmann H., Elger C.E., Bidlingmaier F., Klingmuller D. Expression of the 17beta-hydroxysteroid dehydrogenase type 5 mRNA in the human brain. Mol Cell Endocrinol 2001, 171:165-168.
177. Stell B.M., Brickley S.G., Tang C.Y., Farrant M., Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc Natl Acad Sci U S A 2003, 100:14439-14444.
178. Stewart R.R., Hoge G.J., Zigova T., Luskin M.B. Neural progenitor cells of the neonatal rat anterior subventricular zone express functional GABA(A) receptors. J Neurobiol 2002, 50:305-322.
179. Stoffel-Wagner B., Watzka M., Steckelbroeck S., Ludwig M., Clusmann H., Bidlingmaier F., Casarosa E., Luisi S., Elger C.E., Beyenburg S. Allopregnanolone serum levels and expression of 5 alpha-reductase and 3 alpha-hydroxysteroid dehydrogenase isoforms in hippocampal and temporal cortex of patients with epilepsy. Epilepsy Res 2003, 54:11-19.
180. Stoffel-Wagner B., Watzka M., Steckelbroeck S., Schramm J., Bidlingmaier J.F., Klingmuller D. Expression of 17beta-hydroxysteroid dehydrogenase types 1, 2, 3 and 4 in the human temporal lobe. J Endocrinol 1999, 160:119-126.
181. Stoffel-Wagner B., Watzka M., Steckelbroeck S., Schwaab R., Schramm J., Bidlingmaier F., Klingmuller D. Expression of CYP19 (aromatase) mRNA in the human temporal lobe. Biochem Biophys Res Commun 1998, 244:768-771.
182. Stoffel-Wagner B., Watzka M., Steckelbroeck S., Wickert L., Schramm J., Romalo G., Klingmuller D., Schweikert H.U. Expression of 5alpha-reductase in the human temporal lobe of children and adults. J Clin Endocrinol Metab 1998, 83:3636-3642.
183. Suzuki M., Wright L.S., Marwah P., Lardy H.A., Svendsen C.N. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci U S A 2004, 101:3202-3207.
184. Swaab D.F., Bao A.M., Lucassen P.J. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005, 4:141-194.
185. Then B.F., Kumpfel T., Trenkwalder C., Rupprecht R., Holsboer F. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology 1999, 53:772-777.
186. Thigpen A.E., Silver R.I., Guileyardo J.M., Casey M.L., McConnell J.D., Russell D.W. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993, 92:903-910.
187. Uzunova V., Sampson L., Uzunov D.P. Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action. Psychopharmacology (Berl) 2006, 186:351-361.
188. Vallee M., Mayo W., Koob G.F., Le M.M. Neurosteroids in learning and memory processes. Int Rev Neurobiol 2001, 46:273-320.
189. Vowinckel E., Reutens D., Becher B., Verge G., Evans A., Owens T., Antel J.P. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 1997, 50:345-353.
190. Wang J.M., Irwin R.W., Liu L., Chen S., Brinton R.D. Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent. Curr Alzheimer Res 2007, 4:510-517.
191. Wang J.M., Liu L., Irwin R.W., Chen S., Brinton R.D. Regenerative potential of allopregnanolone. Brain Res Rev 2008, 57:398-409.
192. Wang J.M., Singh C., Liu L., Irwin R.W., Chen S., Chung E.J., Thompson R.F., Brinton R.D. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2010, 107:6498-6503.
193. Webber K.M., Stocco D.M., Casadesus G., Bowen R.L., Atwood C.S., Previll L.A., Harris P.L., Zhu X., Perry G., Smith M.A. Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease. Mol Neurodegener 2006, 1:14.
194. Wegner F., Kraft R., Busse K., Hartig W., Schaarschmidt G., Schwarz S.C., Schwarz J., Hevers W. Functional and molecular analysis of GABA receptors in human midbrain-derived neural progenitor cells. J Neurochem 2008, 107:1056-1069.
195. Weill-Engerer S., David J.P., Sazdovitch V., Liere P., Eychenne B., Pianos A., Schumacher M., Delacourte A., Baulieu E.E., Akwa Y. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab 2002, 87:5138-5143.
196. Wojtal K., Trojnar M.K., Czuczwar S.J. Endogenous neuroprotective factors: neurosteroids. Pharmacol Rep 2006, 58:335-340.
197. Wozniak A., Hutchison R.E., Morris C.M., Hutchison J.B. Neuroblastoma and Alzheimer's disease brain cells contain aromatase activity. Steroids 1998, 63:263-267.
198. Wu F.S., Gibbs T.T., Farb D.H. Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-d-aspartate receptor. Mol Pharmacol 1991, 40:333-336.
199. Yague J.G., Munoz A., de Monasterio-Schrader P., Defelipe J., Garcia-Segura L.M., Azcoitia I. Aromatase expression in the human temporal cortex. Neuroscience 2006, 138:389-401.
200. Yasuno F., Ota M., Kosaka J., Ito H., Higuchi M., Doronbekov T.K., Nozaki S., Fujimura Y., Koeda M., Asada T., Suhara T. Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry 2008, 64:835-841.
201. Yu L., Romero D.G., Gomez-Sanchez C.E., Gomez-Sanchez E.P. Steroidogenic enzyme gene expression in the human brain. Mol Cell Endocrinol 2002, 190:9-17.